Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The company's principal product is Zofin™, derived from amniotic fluid and manufactured to retain naturally occurring extracellular vesicles, proteins, and cell-secreted nanoparticles. It also manufactures Patient Pure X™, a proprietary autologous biologic containing a nanoparticle fraction precipitated from a patient's own peripheral blood. The company's portfolio of products, referred to as RAAM Products, is used in the healthcare industry and administered through doctors and clinics. Zeo ScientifiX, Inc. operates its extracellular vesicle processing laboratory in Davie, Florida, for research and development and the manufacturing and processing of anti-aging and cellular therapy derived products that it sells and distributes to customers. The company's products are all manufactured in FDA-registered, cGMP-compliant laboratory facilities. Zeo ScientifiX, Inc. pursues clinical research and commercial sales strategies compliant with Florida's SB 1768, which authorizes licensed physicians to administer non-FDA-approved stem cell and other human tissue-derived therapies for orthopedic, wound care, and pain management indications.
Zeo ScientifiX, Inc. generates revenue through the sale and distribution of its biological therapeutics, primarily Zofin™ and Patient Pure X™, to healthcare providers such as doctors and clinics. The company also markets and distributes additional products incorporating its proprietary ingredients for topical aesthetic applications. Revenue is derived from the sale of these biologics and related services to providers who administer the treatments to patients. The company has expanded its product line to target specific indications compliant with SB 1768, including pain, wound care, and orthopedics. Zeo ScientifiX, Inc. intends to grow its in-house and independent sales force to increase market penetration and distribution of its products. The company also seeks to build strategic partnerships with universities, hospitals, biotech firms, and global distribution networks to expand sales into the medical aesthetic market and other therapeutic areas.
Zeo ScientifiX, Inc. does not report distinct operational segments in its business description.
Zeo ScientifiX, Inc. positions itself within the competitive regenerative medicine and cell therapy sectors by emphasizing leadership in research, quality, safety, and regulatory compliance for biologics. The company competes with other perinatal and autologous product manufacturers, including companies such as Kimera Labs, Frontier Biologics, Platinum Biologics, Benev Company Inc., Exocel Bio, Re-gen Active Lab, Neobiosis, MiMedix Group, Inc., Invitrx Therapeutics, DermaSciences, Signature Biologics, Direct Biologics, and Vitti Labs LLC. Zeo ScientifiX, Inc. differentiates itself through its ethically sourced birth tissue-derived products, cGMP-compliant manufacturing, and its ability to leverage real-world safety and outcome data from providers under SB 1768 to support future FDA submissions. The company aims to distinguish itself by obtaining biologics license status from the FDA to provide advantages over competitors, including acceleration for acceptance in traditional insurance plans and superior customer education on product benefits.
Zeo ScientifiX, Inc. serves a broad-based customer base of healthcare providers throughout the United States and worldwide, including doctors and clinics that administer its RAAM products to patients. The company's customer base is not dependent on any single or limited number of customers, as its distribution network continues to expand. The company markets its products to providers specializing in regenerative medicine, wound care, orthopedics, and aesthetic treatments, with a growing focus on the medical aesthetic market through topical applications of its proprietary ingredients.